HTG Molecular Diagnostics to Announce Q1 2021 Financial Results and Host Conference Call on Thursday, May 13
HTG Molecular Diagnostics (Nasdaq: HTGM) announced it will report its financial results for Q1 2021 on May 13, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HTG Molecular Diagnostics (Nasdaq: HTGM) announced it will report its financial results for Q1 2021 on May 13, 2021, after market close. A conference call will follow at 4:30 PM Eastern Time to discuss these results and provide a corporate update.
HTG specializes in next-generation sequencing (NGS)-based molecular profiling, utilizing its proprietary HTG EdgeSeq technology to automate complex molecular profiling from various sample types.
Positive
- HTG's proprietary EdgeSeq technology facilitates advanced molecular profiling, which is crucial for precision medicine.
Negative
- None.
Details
News Market Reaction – HTGM
The recorded move for HTGM in the trading session of this news was -3.84%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TUCSON, Ariz., May 04, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the quarter ended March 31, 2021 after the market close on Thursday, May 13, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
Conference Call & Webcast Details:
| Date: | Thursday, May 13 |
| Time: | 4:30 pm Eastern Time |
| Toll Free: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13719223 |
| Webcast: | http://public.viavid.com/index.php?id=144644 |
About HTG:
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.